MSH6 and endometrial carcinoma: In one study report, two cases of recurrent POLE ultra-mutated and MSH6 hyper-mutated endometrial carcinoma refractory to conventional surgical and chemotherapeutic treatments were effectively treated with the anti-PD-1 monoclonal antibody Nivolumab [168].